©The Author(s) 2025.
World J Hepatol. Dec 27, 2025; 17(12): 113658
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113658
Published online Dec 27, 2025. doi: 10.4254/wjh.v17.i12.113658
Figure 4 Mean reductions from baseline to end of treatment in nonalcoholic fatty liver disease fibrosis scores.
NFS: Nonalcoholic fatty liver disease fibrosis; norUDCA: Norursodeoxycholic acid.
- Citation: Panuganti VK, Alluri CV, Mohammad J, Dundigalla MR, Madala PK, KSSVV S, Shaik A. Phase III, multicenter, randomized, double-blind, placebo-controlled study of norursodeoxycholic acid in metabolic dysfunction-associated steatotic liver disease patients. World J Hepatol 2025; 17(12): 113658
- URL: https://www.wjgnet.com/1948-5182/full/v17/i12/113658.htm
- DOI: https://dx.doi.org/10.4254/wjh.v17.i12.113658